Developing bispecific IgA as an engager of neutrophils

IgA antibodies have been shown to be superior in activating neutrophils in comparison to IgG⁠. The goal of this project is to develop and test an IgA molecule that can bind a tumor target while simultaneously blocking CD47, which is a “don’t eat me”-signal commonly found on tumor cells⁠. This approach may induce superior tumor killing by neutrophils, while simultaneously reducing the toxicity and resistance seen in commonly used antibody therapies⁠.

Contact 
Ida van der Peet